Clinical Trial Update: Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 gene therapy trial called AlphaCN for Crigler-Najjar syndrome type I is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crigler-najjar Syndrome Type

Drugs mentioned

• AlphaCN

Snippet

Sponsor: Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare | Conditions: Crigler-Najjar Syndrome Type I | Phase 1, Phase 2 | Status: RECRUITING